Fundz

Watching Castle Biosciences, Inc.? See every signal: funding, hires, M&A, contracts, sentiment.

Book a demoChoose your plan
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →
Back to SEC Filings
Financial ResultsItem 2.02 · 8-KLOW RiskNeutral

Castle Biosciences, Inc.

castlebiosciences.com
Filed: Jul 30, 2026CIK: 0001447362Biotechnology
Full company profileView on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

Castle Biosciences announced Q2 2026 financial results on July 30, 2026, providing stakeholders with key performance metrics and operational insights for the quarter ended June 30, 2026.

Key Takeaways

Company released Q2 2026 financial results highlighting operational performance and key metrics

Press release details are included as Exhibit 99.1 but not filed for regulatory purposes

1 more takeaway

Filing Overview

Form Type8-K
Filing DateJul 30, 2026
Item2.02
CategoryFinancial Results
CIK0001447362
Accession #cstl-20260730
Risk LevelLOW
SentimentNeutral
Signalinformational
Topics
earnings

What This Means

The company is reporting financial results. Look for revenue trends, profitability changes, and forward guidance.
View Full Filing on SEC.govBrowse More Filings

Castle Biosciences, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.